Medicus Pharma Ltd. Common Stock (MDCX)
Automate Your Wheel Strategy on MDCX
With Tiblio's Option Bot, you can configure your own wheel strategy including MDCX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDCX
- Rev/Share 0.0
- Book/Share -0.0432
- PB -31.7309
- Debt/Equity -0.2596
- CurrentRatio 0.9178
- ROIC 53.6369
- MktCap 34163463.0
- FreeCF/Share -1.0431
- PFCF -1.7578
- PE -2.1308
- Debt/Assets 0.0237
- DivYield 0
- ROE -7.1137
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Medicus Pharma teams with Reliant AI for study push – ICYMI
Published: December 26, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) earlier this week shared details of a planned collaboration with Reliant AI to improve clinical trial execution through artificial intelligence. The company's chief medical officer, Dr Faisal Mehmud, said the collaboration will focus initially on supporting the development of Teverelix, a compound that was acquired through Medicus's takeover of Antev during the summer.
Read More
Medicus Pharma signs non-binding AI collaboration to support clinical trials
Published: December 22, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) said on Monday it has entered into a letter of intent with Reliant AI Inc to collaborate on the development of an artificial-intelligence-powered data analytics platform aimed at improving the execution of its clinical trials. The Nasdaq-listed biotechnology company said the proposed platform would integrate Reliant's generative AI technology with Medicus' clinical, operational and proprietary datasets to support data-driven decision-making across its development pipeline.
Read More
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
Published: December 22, 2025 by: Accesswire
Sentiment: Neutral
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary retention (AURr) and high CV risk prostate cancer collectively representing ~$6 billion in potential market opportunity PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has entered into non-binding letter of intent (LOI) with Reliant …
Read More
Medicus Pharma completes enrollment for Phase 2 basal cell carcinoma study
Published: December 15, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) announced that it has completed enrollment of 90 patients in its Phase 2 clinical study evaluating a non-invasive treatment for basal cell carcinoma (BCC) of the skin. The study, known as SKNJCT-003, is assessing the safety and efficacy of the company's doxorubicin microneedle array (D-MNA) in patients with nodular BCC.
Read More
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published: December 05, 2025 by: Accesswire
Sentiment: Neutral
Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that it has entered into a warrant inducement agreement for the immediate exercise of the total outstanding Series A Warrants and Series B Warrants that the Company issued on July 14, 2025 (the "Warrants").
Read More
Medicus Pharma names president Carolyn Bonner as new CFO
Published: December 01, 2025 by: Proactive Investors
Sentiment: Neutral
Medicus Pharma (NASDAQ:MDCX) announced that Carolyn Bonner, who currently serving as the company's president, has been appointed to the role of chief financial officer (CFO). Bonner has been acting CFO since September 12, filling the role during the medical leave of former finance chief Jim Quinlan, who has now resigned from the company for health reasons.
Read More
Medicus Pharma secures UK approval to expand Phase 2 trial of non-invasive skin cancer treatment
Published: November 13, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) said on Thursday it has received full regulatory and ethical approvals in the UK to expand its ongoing Phase 2 clinical trial evaluating its Doxorubicin Microneedle Array (D-MNA) treatment for basal cell carcinoma (BCC), a common form of skin cancer. The UK's Medicines and Healthcare products Regulatory Agency, Health Research Authority and Wales Research Ethics Committee granted the approvals, allowing Medicus to add clinical sites in the country to its ongoing study (SKNJCT-003), which is already underway across nine sites in the US.
Read More
Medicus Pharma, Gorlin Syndrome Alliance partner to expand SKINJECT access
Published: October 29, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) has partnered with the Gorlin Syndrome Alliance (GSA) to expand compassionate access to its investigational microneedle therapy, SKINJECT, for patients suffering from Gorlin Syndrome, a rare genetic condition that causes recurring skin cancers. Under the collaboration, the two groups will pursue an Expanded Access Investigational New Drug (IND) program with the US Food and Drug Administration (FDA) to allow patients with multiple or inoperable basal cell carcinomas (BCCs) to receive SKINJECT under physician supervision.
Read More
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) lesions over lifetime Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) lesions over lifetime
Read More
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Published: October 29, 2025 by: Accesswire
Sentiment: Neutral
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) lesions over lifetime PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 29, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company's investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from …
Read More
Medicus Pharma doses first patient in UAE Phase 2 skin cancer study
Published: October 22, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) announced that the first patient has been treated in the United Arab Emirates (UAE) as part of its SKNJCT-004 Phase 2 clinical study evaluating a non-invasive treatment for basal cell carcinoma (BCC) of the skin. The 36-participant study is being conducted across six sites in the UAE, with Cleveland Clinic Abu Dhabi (CCAD) serving as the principal investigator.
Read More
Medicus Pharma receives coverage from Stonegate Capital Partners
Published: September 24, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) announced that Stonegate Capital Partners has initiated coverage on the company. Stonegate analysts wrote that with the closing of its $8 million debenture financing, Medicus has cash of $9.7 million as of the second quarter of 2025, which extends the company's runway into 2026.
Read More
Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)
Published: September 24, 2025 by: Newsfile Corp
Sentiment: Neutral
Dallas, Texas--(Newsfile Corp. - September 24, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX): Stonegate Capital Partners initiates their coverage on Medicus Pharma Ltd.
Read More
Medicus Pharma secures $8M in non-dilutive debenture financing
Published: September 18, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) announced Thursday that it has entered into a financing agreement with Yorkville Advisors Global, through its fund YA II PL, Ltd., raising $8 million in non-dilutive debenture financing.
Read More
Medicus Pharma begins Phase 2 clinical study in UAE to treat BCC
Published: September 08, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-004 Phase 2 clinical study, a non-invasive treatment for Basal Cell Carcinoma (BCC) of the skin, has begun patient recruitment in Cleveland clinic Abu Dhabi in the United Arab Emirates (UAE). The biotech/life sciences company said the study is expected to randomize 36 patients in four sites in UAE.
Read More
Medicus Pharma closes Antev acquisition; sees $6B market potential
Published: September 02, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) reported that it has completed its previously announced acquisition of Antev Limited, a UK-based clinical-stage drug development company. Medicus said it has acquired 98.6% of the issued and outstanding shares of Antev for total consideration of about US$2.97 million in cash plus 1,603,164 common shares of Medicus.
Read More
Medicus Pharma and HelixNano agree outline deal to develop heat-stable vaccines
Published: August 04, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) has agreed a non-binding memorandum of understanding with Boston-based Helix Nanotechnologies to develop a new generation of vaccines that remain stable at room temperature. The two companies plan to combine HelixNano's technology, which uses messenger ribonucleic acid (mRNA) to instruct the immune system how to fight off infectious diseases, with Medicus's method of delivering vaccines using dissolvable microneedle patches.
Read More
Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025
Published: July 21, 2025 by: Newsfile Corp
Sentiment: Neutral
Executive Chairman & CEO of the Company to Participate in a Fireside Chat Philadelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the scheduling of the Fireside chat of Dr. Raza Bokhari, Executive Chairman and CEO, at the BTIG Virtual Biotech Conference 2025.
Read More
Medicus Pharma submits Type C meeting request to FDA to advance skin cancer treatment
Published: July 08, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) announced that it has submitted a formal request to the US Food and Drug Administration (FDA) for a Type C meeting to discuss the clinical development pathway for its dissolvable doxorubicin-containing microneedle array (D-MNA) product targeting basal cell carcinoma (BCC) of the skin. The company is seeking a meeting during the week of October 6, aiming to gain the agency's approval to fast-track the program and seek feedback on future clinical plans.
Read More
Medicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment
Published: July 04, 2025 by: Seeking Alpha
Sentiment: Positive
Medicus Pharma offers high-risk, high-reward potential with its novel SkinJect patch for basal cell carcinoma and recent Antev acquisition expanding its pipeline. Strong insider/institutional backing and leadership with skin in the game are positives, but ongoing heavy dilution and cash burn are major concerns. FDA approval for SkinJect and Antev's assets is at least two years away; revenue generation is unlikely before 2027-2028, requiring investor patience.
Read More
Medicus to acquire UK biotech Antev in share deal worth up to $65m
Published: June 30, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) has agreed to acquire Antev, a UK-based drug developer working on treatments for prostate conditions, in a share-based deal that could be worth up to US$65 million in future milestone payments. Under the terms of the agreement, Antev shareholders will receive 2.67 million Medicus shares, equivalent to around 17% of the enlarged company, and worth $7.7 million at current prices.
Read More
Medicus Pharma names Andrew Smith as COO, advances BCC and prostate drug studies
Published: June 23, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) said on Monday it has appointed Andrew Smith as chief operating officer, bringing on board a seasoned asset management executive as the company accelerates its clinical development programs in the US, Europe, and the Middle East. Smith, who most recently served as CEO of SR Asset Management until its sale in 2024, brings over 30 years of experience in financial and operational leadership.
Read More
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
Published: June 23, 2025 by: Newsfile Corp
Sentiment: Neutral
Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Basal Cell Carcinoma (BCC) Using Novel Doxorubicin Containing Microneedle Arrays (D-MNA) Philadelphia, Pennsylvania--(Newsfile Corp. - June 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Andrew Smith as Chief Operating Officer.
Read More
Medicus Pharma submits FDA plan to develop microneedle-based treatment for skin cancer in horses
Published: June 09, 2025 by: Proactive Investors
Sentiment: Neutral
Medicus Pharma (NASDAQ:MDCX) said on Monday it has submitted a comprehensive product development plan to the US Food and Drug Administration (FDA) to advance its investigational treatment for external squamous cell carcinoma (SCC) in horses. The plan was submitted under the company's existing Investigational New Animal Drug file and follows the FDA's Minor Use in Major Species designation, which Medicus received in December 2024 for its dissolvable Doxorubicin-containing microneedle array (D-MNA).
Read More
Medicus Pharma appoints KPMG as new auditor, expands global clinical programs
Published: June 06, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) said it has appointed KPMG as its independent registered public accounting firm for the 2025 fiscal year, replacing EisnerAmper following a review process led by the company's audit committee and approved by its board. The transition, announced on June 4, comes as the clinical-stage biotech company ramps up its global operations and research programs.
Read More
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering
Published: June 02, 2025 by: Newsfile Corp
Sentiment: Neutral
Philadelphia, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced public offering of 2,260,000 units, on a "best-efforts" basis, at a price of $3.10 per unit.
Read More
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
Published: May 29, 2025 by: Newsfile Corp
Sentiment: Neutral
Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its public offering of 2,260,000 units, on a "best-efforts" basis, at a price of $3.10 per unit.
Read More
Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy
Published: May 22, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) has received regulatory approval from the UAE Department of Health to begin a Phase 2 clinical trial evaluating its non-invasive therapy for basal cell carcinoma (BCC) of the skin. The study, designated SKNJCT-004, will enroll up to 36 patients across four medical centers in the UAE.
Read More
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Published: May 22, 2025 by: Newsfile Corp
Sentiment: Neutral
The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has received study may proceed approval from the UAE DOH to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC of the skin.
Read More
Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio
Published: May 12, 2025 by: Benzinga
Sentiment: Positive
In April, Medicus Pharma Ltd. MDCX agreed to acquire all of Antev's issued and outstanding shares on a share exchange.
Read More
About Medicus Pharma Ltd. Common Stock (MDCX)
- IPO Date 2024-11-15
- Website https://medicuspharma.com
- Industry Biotechnology
- CEO Raza Bokhari
- Employees 12